|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Factor X Activity
Test Code30773
CPT Codes
85260<br /> Limited Access Code
Preferred Specimen
1 mL platelet-poor plasma collected in 3.2% sodium citrate (light-blue top) tube
Minimum Volume
0.5 mL
Instructions
Platelet-poor plasma: Centrifuge light blue-top tube for 15 minutes at approximately 1500 g within 60 minutes of collection. Using a plastic pipette, remove plasma, taking care to avoid WBS/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. Plasma must be free of platelets (<10,000/mcL). Freeze immediately and ship on dry ice.
Refer to Quest Diagnostics Directory of Services under Specimen Collection section, Coagulation Testing for further information on specimen processing.
Refer to Quest Diagnostics Directory of Services under Specimen Collection section, Coagulation Testing for further information on specimen processing.
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen -20°C: 14 days
Frozen -70°C: 1 year
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolyzed specimens
Methodology
Photometric Clot Detection
Setup Schedule
Set up: Mon-Fri; Report available: Next day
Reference Range
70-150 % of normal
Clinical Significance
This assay measures the FX activity in plasma. This test can help confirm a diagnosis of FX deficiency in patients who present with symptoms associated with FX deficiency [1,2].
According to the National Hemophilia Foundation, FX deficiency affects between 1 in every 500,000 to 1/1,000,000 people in the general population. Because FX deficiency is an autosomal recessive condition, men and women are equally affected.
Symptoms can develop at any age. In addition to congenital FX deficiency, this condition can be acquired secondary to the use of warfarin (Coumadin) and/or vitamin K deficiency [1-3].
Depending on the level of severity, symptoms may include unexplained bruising, bleeding gums, and frequent nosebleeds on the mild end; excessive postsurgical or post-trauma bleeding in moderate-to-severe cases; and hemarthrosis, intramuscular bleeds, and gastrointestinal bleeding in the most severe cases [1-3].
The Factor X Activity, Clotting test can be used to confirm FX deficiency in individuals who present with symptoms associated with prolonged prothrombin time and/or partial thromboplastin time. It should be noted that pregnant women with FX may experience first-trimester miscarriage or postpartum hemorrhaging and should receive consultation by a hematologist and obstetrician prior to delivery [1,2].
References
1. National Hemophilia Foundation. Factor X.
https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Other-Factor-Deficiencies/Factor-X. Accessed
October 3, 2019.
2. AACC. Coagulation factors. Last updated: May 3, 2019. https://labtestsonline.org/tests/coagulation-factors. Accessed October 2, 2019.
3. National Organization for Rare Diseases. Factor X deficiency. https://rarediseases.org/rare-diseases/factor-x-deficiency/. Last updated 2018.
According to the National Hemophilia Foundation, FX deficiency affects between 1 in every 500,000 to 1/1,000,000 people in the general population. Because FX deficiency is an autosomal recessive condition, men and women are equally affected.
Symptoms can develop at any age. In addition to congenital FX deficiency, this condition can be acquired secondary to the use of warfarin (Coumadin) and/or vitamin K deficiency [1-3].
Depending on the level of severity, symptoms may include unexplained bruising, bleeding gums, and frequent nosebleeds on the mild end; excessive postsurgical or post-trauma bleeding in moderate-to-severe cases; and hemarthrosis, intramuscular bleeds, and gastrointestinal bleeding in the most severe cases [1-3].
The Factor X Activity, Clotting test can be used to confirm FX deficiency in individuals who present with symptoms associated with prolonged prothrombin time and/or partial thromboplastin time. It should be noted that pregnant women with FX may experience first-trimester miscarriage or postpartum hemorrhaging and should receive consultation by a hematologist and obstetrician prior to delivery [1,2].
References
1. National Hemophilia Foundation. Factor X.
https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Other-Factor-Deficiencies/Factor-X. Accessed
October 3, 2019.
2. AACC. Coagulation factors. Last updated: May 3, 2019. https://labtestsonline.org/tests/coagulation-factors. Accessed October 2, 2019.
3. National Organization for Rare Diseases. Factor X deficiency. https://rarediseases.org/rare-diseases/factor-x-deficiency/. Last updated 2018.
